Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations (NCT01657682) | Arog Pharmaceuticals, Inc. | 2012-10-01 |
Track Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies automatically
Every clearance here is in the API, with alerts when new ones post.